**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A. Recent policy signals from HHS, including announcements by Secretary Robert F. Kennedy Jr., indicate intent to shift several peptides including BPC-157 back toward Category 1 (“under evaluation”), enabling licensed compounding pharmacies to prepare it under prescription pending final review. The key near-term catalyst is the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, which will evaluate BPC-157 and related substances for the 503A bulks list. Trader sentiment reflects uncertainty around whether formal Category 1 placement occurs before or after that meeting, given the distinction between removal from Category 2 and affirmative listing, as well as ongoing questions about manufacturing standards and clinical evidence thresholds.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoNUOVO
31 ago 2026
August 31, 2026
24%
December 31, 2026
44%
$856 Vol.
August 31, 2026
$168 Vol.
24%
December 31, 2026
$688 Vol.
44%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A. Recent policy signals from HHS, including announcements by Secretary Robert F. Kennedy Jr., indicate intent to shift several peptides including BPC-157 back toward Category 1 (“under evaluation”), enabling licensed compounding pharmacies to prepare it under prescription pending final review. The key near-term catalyst is the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, which will evaluate BPC-157 and related substances for the 503A bulks list. Trader sentiment reflects uncertainty around whether formal Category 1 placement occurs before or after that meeting, given the distinction between removal from Category 2 and affirmative listing, as well as ongoing questions about manufacturing standards and clinical evidence thresholds.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Mercato aperto: Jun 22, 2026, 10:10 PM ET
Volume
$856Data di fine
31 dic 2026Mercato aperto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A. Recent policy signals from HHS, including announcements by Secretary Robert F. Kennedy Jr., indicate intent to shift several peptides including BPC-157 back toward Category 1 (“under evaluation”), enabling licensed compounding pharmacies to prepare it under prescription pending final review. The key near-term catalyst is the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, which will evaluate BPC-157 and related substances for the 503A bulks list. Trader sentiment reflects uncertainty around whether formal Category 1 placement occurs before or after that meeting, given the distinction between removal from Category 2 and affirmative listing, as well as ongoing questions about manufacturing standards and clinical evidence thresholds.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$856Data di fine
31 dic 2026Mercato aperto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A. Recent policy signals from HHS, including announcements by Secretary Robert F. Kennedy Jr., indicate intent to shift several peptides including BPC-157 back toward Category 1 (“under evaluation”), enabling licensed compounding pharmacies to prepare it under prescription pending final review. The key near-term catalyst is the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, which will evaluate BPC-157 and related substances for the 503A bulks list. Trader sentiment reflects uncertainty around whether formal Category 1 placement occurs before or after that meeting, given the distinction between removal from Category 2 and affirmative listing, as well as ongoing questions about manufacturing standards and clinical evidence thresholds.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti